Chemistry:Taminadenant

From HandWiki

Taminadenant (PBF509) is an experimental drug which acts as a selective inhibitor of the adenosine A2A receptor. It is in clinical trials for the treatment of lung cancer, and has also shown potential for applications in the treatment of movement disorders.[1][2][3][4]

References

  1. ↑ "A Novel Antagonist of the Immune Checkpoint Protein Adenosine A2a Receptor Restores Tumor-Infiltrating Lymphocyte Activity in the Context of the Tumor Microenvironment". Neoplasia 19 (7): 530–536. July 2017. doi:10.1016/j.neo.2017.02.004. PMID 28582704. 
  2. ↑ "PBF509, an Adenosine A2A Receptor Antagonist With Efficacy in Rodent Models of Movement Disorders". Frontiers in Pharmacology 9: 1200. 2018. doi:10.3389/fphar.2018.01200. PMID 30405415. 
  3. ↑ "Phase I Study of Taminadenant (PBF509/NIR178), an Adenosine 2A Receptor Antagonist, with or without Spartalizumab (PDR001), in Patients with Advanced Non-Small Cell Lung Cancer". Clinical Cancer Research 28 (11): 2313–2320. June 2022. doi:10.1158/1078-0432.CCR-21-2742. PMID 35254415. 
  4. ↑ "Early Adverse Event Derived Biomarkers in Predicting Clinical Outcomes in Patients with Advanced Non-Small Cell Lung Cancer Treated with Immunotherapy". Cancers 15 (9): 2521. April 2023. doi:10.3390/cancers15092521. PMID 37173987. 



Retrieved from "https://handwiki.org/wiki/index.php?title=Chemistry:Taminadenant&oldid=4031796"